Gables Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,000
Closed -$14.1K – 515
2026
Q2
$14.1K Buy
+3,000
New +$22.1K 0.01% 371

Other funds holding UNCY

Gables Capital Management's UNCY Position: Q3 2026 in Review

Gables Capital Management sold out of Unicycive Therapeutics (UNCY) in Q3 2026, closing a stake of 3,000 shares — an estimated $14.1K sold.

Gables Capital Management first reported a position in UNCY in Q2 2026 and held it in 1 quarter. The position peaked at $14.1K in Q2 2026. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Gables Capital Management reported no remaining Unicycive Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Gables Capital Management sold 3,000 Unicycive Therapeutics shares in Q3 2026, an estimated $14.1K.
  • Gables Capital Management first reported a position in Unicycive Therapeutics in Q2 2026 and held it in 1 quarter.
  • Gables Capital Management's Unicycive Therapeutics position peaked at $14.1K in Q2 2026.
  • 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Gables Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.